• Consensus Rating: Buy
  • Consensus Price Target: $24.00
  • Forecasted Upside: 85.76 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$12.92
▲ +0.08 (0.62%)

This chart shows the closing price for CERT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Certara Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CERT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CERT

Analyst Price Target is $24.00
▲ +85.76% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Certara in the last 3 months. The average price target is $24.00, with a high forecast of $31.00 and a low forecast of $20.00. The average price target represents a 85.76% upside from the last price of $12.92.

This chart shows the closing price for CERT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Certara.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/5/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/4/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/2/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/31/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/31/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/29/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/28/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/27/2022

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/8/2022Berenberg BankInitiated CoverageBuy$23.00Low
8/24/2022Credit Suisse GroupInitiated CoverageOutperform$22.00Low
8/24/2022Morgan StanleyLower TargetEqual Weight$24.00 ➝ $20.00Low
8/17/2022BarclaysLower TargetOverweight$24.00 ➝ $21.00Low
8/10/2022SVB LeerinkLower TargetOutperform$29.00 ➝ $26.00Low
8/10/2022Piper SandlerLower TargetOverweight$28.00 ➝ $25.00Low
7/15/2022SVB LeerinkInitiated CoverageOutperform$29.00Low
7/13/2022BarclaysLower TargetOverweight$25.00 ➝ $24.00N/A
7/1/2022Piper SandlerInitiated CoverageOverweight$28.00Low
3/3/2022Morgan StanleyLower TargetEqual Weight$27.00 ➝ $25.00High
3/3/2022BarclaysLower TargetOverweight$48.00 ➝ $26.00High
1/11/2022Jefferies Financial GroupUpgradeHold ➝ Buy$31.00High
9/17/2021Robert W. BairdBoost TargetOutperform$32.00 ➝ $41.00High
7/23/2021Robert W. BairdInitiated CoverageOutperform$30.00Medium
5/7/2021BarclaysLower TargetOverweight$40.00 ➝ $35.00Medium
3/8/2021Morgan StanleyLower TargetEqual Weight$35.00 ➝ $33.00High
3/5/2021William BlairReiterated RatingOutperformHigh
3/2/2021BarclaysInitiated CoverageOverweight$40.00High
1/5/2021Morgan StanleyInitiated CoverageEqual Weight$35.00N/A
1/5/2021Jefferies Financial GroupInitiated CoverageHold$33.00N/A
1/5/2021Credit Suisse GroupInitiated CoverageNeutral$35.00N/A
1/5/2021William BlairInitiated CoverageOutperformN/A
1/5/2021Bank of AmericaInitiated CoverageBuy$41.00N/A
(Data available from 9/27/2017 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/31/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2022
  • 3 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/30/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/29/2022
  • 4 very positive mentions
  • 17 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
8/28/2022
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2022

Current Sentiment

  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Certara logo
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $12.92
Low: $12.84
High: $13.14

50 Day Range

MA: $17.87
Low: $12.84
High: $24.13

52 Week Range

Now: $12.92
Low: $12.58
High: $45.48

Volume

653,306 shs

Average Volume

679,057 shs

Market Capitalization

$2.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Certara?

The following Wall Street sell-side analysts have issued stock ratings on Certara in the last year: Barclays PLC, Berenberg Bank, Credit Suisse Group AG, Jefferies Financial Group Inc., Morgan Stanley, Piper Sandler, and SVB Leerink LLC.
View the latest analyst ratings for CERT.

What is the current price target for Certara?

7 Wall Street analysts have set twelve-month price targets for Certara in the last year. Their average twelve-month price target is $24.00, suggesting a possible upside of 85.8%. Jefferies Financial Group Inc. has the highest price target set, predicting CERT will reach $31.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $20.00 for Certara in the next year.
View the latest price targets for CERT.

What is the current consensus analyst rating for Certara?

Certara currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CERT will outperform the market and that investors should add to their positions of Certara.
View the latest ratings for CERT.

What other companies compete with Certara?

How do I contact Certara's investor relations team?

Certara's physical mailing address is 100 OVERLOOK CENTER SUITE 101, PRINCETON NJ, 08540. The company's listed phone number is 609-716-7900 and its investor relations email address is [email protected] The official website for Certara is www.certara.com. Learn More about contacing Certara investor relations.